000			01531 a2200409 4500
005			20250513184742.0
264		0	_c19990805
008			199908s 0 0 eng d
022			_a1083-4389
024	7		_a10.1046/j.1523-5378.1999.98005.x _2doi
040			_aNLM _beng _cNLM
100	1		_aSchwartz, H I
245	0	0	_aTwice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. _h[electronic resource]
260			_bHelicobacter _cJun 1999
300			_a121-7 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAnti-Bacterial Agents _xtherapeutic use
650	0	4	_aAnti-Ulcer Agents _xtherapeutic use
650	0	4	_aBismuth _xadverse effects
650	0	4	_aClarithromycin _xadverse effects
650	0	4	_aDouble-Blind Method
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aHelicobacter Infections _xdrug therapy
650	0	4	_aHelicobacter pylori _xdrug effects
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMicrobial Sensitivity Tests
650	0	4	_aMiddle Aged
650	0	4	_aRanitidine _xadverse effects
700	1		_aPerschy, T B
700	1		_aMcSorley, D J
700	1		_aSorrells, S C
773	0		_tHelicobacter _gvol. 4 _gno. 2 _gp. 121-7
856	4	0	_uhttps://doi.org/10.1046/j.1523-5378.1999.98005.x _zAvailable from publisher's website
999			_c10340483 _d10340483